I have been "paper trading" QUIG since it was less than $5, its been on a roll since then and I kick myself for not jumping in. I originally got the idea for QUIG by watching the local news where "Cold Eeze" was given free advertising as a feature story in the mainstream TV media here in Washington D.C. More stuff from the QUIG home page:
The Quigley Corporation (QUIG - OTC BULLETIN BOARD) filed an S-18 in 1990 and became effective on February 7, 1992 with a closing date of August 8, 1992. The number of shares outstanding as of October 23, 1995 were 34,034,141 of which 2,113,433 are free trading units, comprised of 1 share of common stock and 1A, 1B, and 1C exercisable warrants. The Company has submitted all the Required Securities & Exchange Commission filings since inception. In accordance with Securities and Exchange Commission ("Commission") requirements (which requires that a current Prospectus be available throughout the period of time within which warrants may be exercised), in October 1995 Corporate Council filed a Post Effective Amendment to its Registration Statement on Form SB-2. The SB-2 Registration Statement primarily will contain information through June 30, 1995. In certain instances, where deemed relevant, the filing contains further factual information regarding business activities through that period. Filed as part of such Registration Statement will be the Company's certified financial statements for its fiscal year ended September 30, 1994. The Registration Statement (which includes the Preliminary Prospectus and various exhibits filed as part thereof), when filed, was ordered effective by the SEC on October 11, 1995.
UPDATE - REVERSE-SPLIT COMMON STOCK:
On January 11, 1996 The Quigley Corporation(OTC Bulletin Board QUIG), received advise from NASD, that the reverse-split of the company's stock, with one new share for every ten presently issued and outstanding shares, as was implemented by the Board of Directors on December 22, 1995, was effective at the opening of business January 11, 1996.
Corporate Overview
The magnitude of the cold remedy marketplace is in excess of $4 billion in sales (Source: LFC & Co.; market research estimate.) and in spite of this vast expenditure, there is still no cure amongst the current array of antihistamines and other varying remedies. There have been no successful remedies until the formulation of COLD-EEZE, where we now have a product that reduces the duration and severity of the Common Cold. Our Company is currently seeking established credible distribution organizations to act as our exclusive partner in bringing this revolutionary cold therapy product to the vast consumer marketplaces worldwide.
EXCLUSIVE WORLDWIDE RIGHTS have been granted to the Corporation by John C. Godfrey Ph.D., an organic chemist and the patent holder
of a zinc gluconate lozenge formulation, which shortens the duration and severity of the common cold. Under an FDA-approved Investigational New Drug Application filed by Dartmouth College, a randomized double-blind placebo-controlled study conducted at Dartmouth College Health Service, Hanover, New Hampshire, USA, concluded that treatment with the zinc gluconate lozenge formulation, initiated within 48 hours of symptom onset, resulted in a 42 per cent reduction in the total duration of the common cold.
The product is patented in the following major markets:
United States: No. 4 684 528 (August 4, 1987) AND No. 4 758 439 (July 19, 1988)
Germany: No. 3,587,766 (March 2, 1994)
France & Italy: No. EP 0 183 840 B1 (March 2, 1994)
Sweden. No. 0 183 840 (March 2, 1994)
Canada: No. 1 243 952 (November 1, 1988)
Great Britain: No. 2 179 536 (December 21, 1988)
Japan: Pending.
On May 22,1992, "Zinc and the Common Cold, a Controlled Clinical Study," by Dr. Godfrey et.al., was published in England, in the Journal of International Medical Research. (Vol.20, No.3, Pgs.234-246) This new, patented, pleasant-tasting formulation delivers 93 percent of the active zinc to the mucosal surfaces. The user has the same sequence of symptoms as in the absence of treatment, but goes through the phases at a much accelerated rate and with reduced symptom severity. The formulation can also be used in chewing gum. We believe we can capitalize on this Unique Selling Proposition. Coupled with the magnitude of the cold remedy marketplace, the potential competitive strength and uniqueness of this breakthrough product will continue to inspire very positive interest. |
